DFN-02 Open Label Safety Study in Patients With Acute Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

March 31, 2016

Conditions
Acute Migraine
Interventions
DRUG

DFN-02

Active Experimental Drug

Trial Locations (24)

14221

Upstate Clinical Research Associates LLC, Williamsville

14226

Dent Neurologic Institute, Amherst

19107

Thomas Jefferson University, Philadelphia

30080

Carman Research, Smyrna

32751

Florida Clinical Research Center, LLC, Maitland

33351

Neurology Clinical Research, Inc, Sunrise

34201

Florida Clinical Research Center, Bradenton

45255

Community Research, Cincinnati

48104

Michigan Head Pain & Neurological Institute, Ann Arbor

65807

Clinvest/A Division of Banyan Group, Inc., Springfield

75231

Future Search Trials of Dallas, LP, Dallas

76022

Protenium Clinical Research, LLC, Bedford

78731

FutureSearch Trials of Neurology, LP, Austin

85023

Arizona Research Center, Phoenix

87102

Albuquerque Clinical Trials, Inc., Albuquerque

90404

California Medical Clinic for Headache, Santa Monica

90806

Collaborative Neuroscience Network, LLC, Long Beach

92408

Breakthrough Clinical Trials, San Bernardino

94109

San Francisco Clinical Research Center, San Francisco

94305

Stanford University Medical Center, Stanford

96001

Northern California Clinical Research Center, Redding

06824

Associated Neurologists of Southern CT, P.C., Fairfield

02740

Novex Clinical Research, New Bedford

02472

MedVadis Research Corporation, Watertown

All Listed Sponsors
lead

Dr. Reddy's Laboratories Limited

INDUSTRY